Daily Pill Helps People Lose Weight, Combines GLP-1 With Other Drug
Experimental weight-loss pill amycretin, developed by Novo Nordisk, helps users lose up to 13% of body weight in 3 months by mimicking GLP-1 and amylin hormones. Higher doses led to more weight loss but also increased side effects like nausea and vomiting. Further clinical trials needed for full assessment.
Reference News
GLP-1 analogue drugs like Wegovy have led to significant weight loss, prompting high demand. Companies are developing oral versions, with Novo Nordisk's amycretin showing promising early results, leading to weight loss faster than injectable semaglutide. Amycretin targets GLP-1 and amylin receptors, potentially offering a more convenient option for obesity management. Larger trials are ongoing to confirm safety and efficacy.
Experimental weight-loss pill amycretin, developed by Novo Nordisk, helps users lose up to 13% of body weight in 3 months by mimicking GLP-1 and amylin hormones. Higher doses led to more weight loss but also increased side effects like nausea and vomiting. Further clinical trials needed for full assessment.